{"id":3532,"date":"2026-11-19T09:36:17","date_gmt":"2026-11-19T09:36:17","guid":{"rendered":"https:\/\/newsraise.com\/in\/2026\/11\/19\/micrornas-gallbladder-cancer-biomarkers\/"},"modified":"2026-11-19T09:36:17","modified_gmt":"2026-11-19T09:36:17","slug":"micrornas-gallbladder-cancer-biomarkers","status":"publish","type":"post","link":"https:\/\/newsraise.com\/in\/2026\/11\/19\/micrornas-gallbladder-cancer-biomarkers\/","title":{"rendered":"MicroRNAs emerge as key biomarkers and therapeutic targets in gallbladder cancer"},"content":{"rendered":"\n<!-- Quick Adsense WordPress Plugin: http:\/\/quickadsense.com\/ -->\n<div class=\"9fece8afa224fd09e54b043d0febfb58\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- NR ATF -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-8898941184964366\"\r\n     data-ad-slot=\"4839033563\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>Gallbladder carcinoma (GBC) remains one of the most lethal cancers of the biliary tract, with late\u2011stage diagnosis, limited treatment options and poor survival rates. New research consolidates evidence that microRNAs (miRNAs) function as powerful post\u2011transcriptional regulators of gene expression and could reshape both prognostic assessment and therapeutic strategies for this disease.<\/p>\n<h2>Epidemiology and current clinical challenges<\/h2>\n<p>Worldwide, GBC affects roughly 2.3 per 100,000 people, accounting for 1.2% of all cancer diagnoses and 1.7% of cancer deaths. According to GLOBOCAN 2022 data that separate GBC from cholangiocarcinoma, the disease generates 122,491 new cases and 89,055 deaths each year, ranking it the 22nd most common cancer and the 17th deadliest malignancy globally. The gallbladder, a small cystic organ beneath the liver that stores and concentrates bile, can develop malignancy through a cascade that begins with chronic inflammation, gallstones, obesity, viral hepatitis, heavy\u2011metal exposure, genetic predisposition and anatomical abnormalities. These risk factors drive metaplastic changes that progress from dysplasia to carcinoma in situ and ultimately invasive carcinoma.<\/p>\n<p>Because the disease often progresses without symptoms, most patients are diagnosed at advanced stages. Survival data illustrate the stark contrast: five\u2011year survival exceeds 90% for Stage\u202fI disease but falls to about 30% for Stage\u202fIII and IV, based on AJCC\/UICC staging criteria. Surgical resection remains the sole curative option, underscoring the urgent need for reliable early\u2011diagnostic biomarkers and novel therapeutic targets.<\/p>\n<h2>MicroRNAs as emerging biomarkers<\/h2>\n<p>MicroRNAs are short, approximately 22\u2011nucleotide, non\u2011coding RNA molecules transcribed from DNA into hairpin precursors. They regulate gene expression by binding to the 3\u2032\u2011untranslated region of target messenger RNAs, thereby inhibiting translation or promoting degradation. In GBC, several miRNAs have been repeatedly implicated across retrospective human tissue studies, in\u2011vitro cell\u2011culture experiments and animal models.<\/p>\n<p>The review highlights five miRNAs with the strongest evidence base: miRNA\u2011155, miRNA\u2011146b\u20115p, miRNA\u2011141, miRNA\u2011195\u20115p and miRNA\u2011335. miRNA\u2011155 is frequently documented in retrospective human tissue cohorts as a prognostic marker. miRNA\u2011146b\u20115p has been examined both in cell\u2011culture models and tissue cohorts, emerging as a prognostic biomarker and a potential therapeutic target; functional assays show it can induce apoptosis and cause G1\u2011phase cell\u2011cycle arrest, thereby inhibiting tumor progression. miRNA\u2011141, a member of the miRNA\u2011200 family, has been linked to regulation of epithelial\u2011mesenchymal transition (EMT) and cell proliferation in multiple cancers, and its expression correlates with prognostic outcomes in GBC. miRNA\u2011195\u20115p demonstrates therapeutic potential by suppressing oncogenic signaling pathways, notably the Wnt\/\u03b2\u2011catenin cascade, while miRNA\u2011335 has been associated with chemoresistance and prognostic value in clinical studies.<\/p>\n<p>Additional miRNAs are noted for their mechanistic relevance. miRNA\u201121 suppresses the tumor\u2011suppressor PTEN, thereby promoting proliferation, migration and invasion in GBC cells. Conversely, miRNA\u2011145\u20115p is down\u2011regulated in tumor tissue; its restoration activates direct and indirect targets of signal transducer and activator of transcription 1 (STAT1), suggesting a tumor\u2011suppressive role.<\/p>\n<h2>Pathway modulation and therapeutic implications<\/h2>\n<p>MicroRNAs influence several key signaling pathways that drive GBC pathogenesis. The PI3K\/AKT pathway, the Wnt\/\u03b2\u2011catenin axis, epidermal growth factor receptor (EGFR) signaling and the JAK\/STAT cascade are all modulated by specific miRNAs. For instance, miRNA\u201121\u2019s inhibition of PTEN leads to hyper\u2011activation of the PI3K\/AKT pathway, while miRNA\u2011195\u20115p\u2019s suppression of Wnt\/\u03b2\u2011catenin signaling curtails tumor growth. Constitutive activation of STAT3 has been reported in GBC and correlates with advanced disease stage and poor prognosis, positioning STAT3\u2011targeting miRNAs as attractive candidates for future interventions.<\/p>\n<p>The functional impact of miRNA\u2011146b\u20115p\u2014inducing apoptosis and G1 arrest\u2014exemplifies how miRNA manipulation could translate into therapeutic benefit. By restoring or mimicking tumor\u2011suppressive miRNAs, or by inhibiting oncogenic miRNAs such as miRNA\u201121, researchers aim to disrupt the molecular circuitry that sustains malignancy.<\/p>\n<p>Beyond their mechanistic roles, miRNAs hold promise as non\u2011invasive biomarkers. Their stability in circulation allows detection in blood samples, offering a potential route for early diagnosis and monitoring of treatment response. However, the review notes a persistent gap in clinically validated early\u2011diagnostic tools for GBC, emphasizing the need for further translational research.<\/p>\n<h2>Historical context of biomarkers<\/h2>\n<p>The concept of a biomarker has evolved over decades. The term \u201cbiochemical marker\u201d appeared in 1949, while \u201cbiological marker\u201d was introduced in 1957. A formal definition emerged in 1973, describing biomarkers as the presence or absence of biological material. In 2000, the National Institutes of Health (NIH) Biomarkers Definitions Working Group provided a widely accepted definition for clinical pharmacology, and the U.S. Food and Drug Administration (FDA) later categorized biomarkers into diagnostic, prognostic, predictive, safety and monitoring groups. Within this framework, miRNAs are positioned as diagnostic and prognostic biomarkers that can inform disease presence, progression and therapeutic response.<\/p>\n<p>Collectively, the evidence underscores a shift toward molecularly guided management of gallbladder carcinoma. By integrating miRNA profiling into clinical workflows, physicians may soon achieve earlier detection, more accurate prognostication and personalized therapeutic regimens that move beyond the current reliance on surgical resection alone.<\/p>\n<p>Continued investigation into the five highlighted miRNAs\u2014miRNA\u2011155, miRNA\u2011146b\u20115p, miRNA\u2011141, miRNA\u2011195\u20115p and miRNA\u2011335\u2014along with broader miRNA panels, is essential to bridge the existing diagnostic gap and to develop targeted therapies that could improve survival for patients confronting this aggressive cancer.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>A recent review highlights specific microRNAs that regulate critical pathways in gallbladder carcinoma, offering new avenues for early diagnosis and targeted therapy.<\/p>\n","protected":false},"author":3,"featured_media":3533,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[299],"tags":[4021,4022,4020,4019,3117],"class_list":["post-3532","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-biomarkers","tag-cancer-research","tag-gallbladder-carcinoma","tag-microrna","tag-oncology","entry"],"_links":{"self":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/3532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/comments?post=3532"}],"version-history":[{"count":0,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/3532\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media\/3533"}],"wp:attachment":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media?parent=3532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/categories?post=3532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/tags?post=3532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}